Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in patients with recurrent high-grade neuroendocrine cervical cancer: a Neuroendocrine Cervical Tumor Registry (NeCTuR) study.

Michael Frumovitz,Gary B Chisholm,Anuja Jhingran,Preetha Ramalingam,Alejandra Flores-Legarreta,Priya Bhosale,Naomi R Gonzales,R Tyler Hillman,Gloria Salvo

American journal of obstetrics and gynecology（2023）

引用 5|浏览11

暂无评分

摘要

Combination therapy with topotecan, paclitaxel, and bevacizumab was an active regimen in women with recurrent high-grade neuroendocrine cervical cancer and improved progression-free survival while decreasing the hazard ratio for disease progression.

查看译文

关键词

cervical cancer,chemotherapy,high-grade neuroendocrine carcinoma,paclitaxel,small-cell carcinoma,topotecan

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要